Selective TACE Inhibitor Design via Hydrazone Substituent Engineering

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for a TNF-α production inhibitor that selectively inhibits TACE without affecting MMPs, to treat TNF-α-related diseases while minimizing adverse effects on the body.

Innovation Solution

The development of (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione, which exhibits a selective TACE inhibitory effect with minimal MMP inhibition, formulated into a pharmaceutical for topical administration to treat skin diseases and other TNF-α-related conditions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If a compound that inhibits both MMP and TACE is used, then TACE inhibitory effect is achieved, but MMP inhibition causes hypertrophic degeneration on cartilage growth plates and other side effects

Engineering Contradiction:

ImproveTACE inhibitory effectVSAvoidMMP inhibition side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention segments the inhibition function by designing a compound that selectively targets TACE while sparing MMP. The hydrazone structure with specific substituents (aromatic ring with electron-withdrawing groups at ortho and para positions) creates steric and electronic characteristics that allow selective binding to TACE's zinc catalytic site while preventing binding to MMP's zinc site, thus achieving functional segmentation of enzyme inhibition.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The invention applies local quality by introducing specific substituent patterns at particular positions of the hydrazone molecule. The electron-withdrawing groups (such as halogens, nitro, or cyano groups) at ortho and/or para positions relative to the hydrazone linkage create localized electronic and steric properties that are critical for selective TACE inhibition. This local modification of molecular properties enables discrimination between TACE and MMP binding.

Inventive Principle:

Principle #3Local quality

2Object-affected harmful factors

If a compound with high TACE selectivity is developed, then MMP-related side effects are reduced, but the compound must maintain sufficient TACE inhibitory activity

Engineering Contradiction:

ImproveMMP-related side effectsVSAvoidTACE inhibitory activity

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The invention utilizes parameter changes by systematically varying the electronic and steric parameters of the hydrazone molecule. By changing the nature, position, and strength of electron-withdrawing substituents, the compound's affinity for TACE's zinc site is optimized while maintaining selectivity against MMP. The parameters of substituent type (halogen, nitro, cyano), position (ortho, meta, para), and number of substituents are adjusted to achieve the desired balance between activity and selectivity.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentEP3006437B1(+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione and drug containing same

Publication Date: 2020.08.05 KAKEN PHARMA CO LTD

AI summary

Provided is (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione or a salt thereof. Also provided is a drug containing as the active ingredient (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione or a salt thereof.